The MSC curtain that stops the immune system

Immunology Letters

Volumn 168, Issue 2, 2015, Pages 136-139

  Caplan, Arnold I ^a   Sorrell, J Michael ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell based therapy; Immunomodulatory; Mesenchymal Stem Cells; Pericytes; Trophic

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37;

ARTICLE; CELL ASSAY; CELL FUNCTION; CELLULAR DISTRIBUTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; MACROPHAGE; MESENCHYMAL STEM CELL; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE REGENERATION; CELL LINEAGE; CYTOLOGY; HEMATOPOIESIS; IMMUNE SYSTEM; IMMUNOLOGY; MESENCHYMAL STROMA CELL; PERICYTE; PHYSIOLOGY; REGENERATION; TUMOR MICROENVIRONMENT;

CELL LINEAGE; CELLULAR MICROENVIRONMENT; HEMATOPOIESIS; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; MESENCHYMAL STROMAL CELLS; PERICYTES; REGENERATION; SIGNAL TRANSDUCTION;

EID: 84949623173     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.06.005     Document Type: Article

References (62)

1. Li W., Huang Y., Su J., Han Y., Li J., Chen X., Cao K., Chen Q., Shou P., Zhang L., Yuan Z.R., Roberts A.I., Shi S., Le A.D., Shi Y. Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Differ. 2012, 19:1505-1513.
2. Brockes J.P., Kumar A. Plasticity and reprogramming of differentiated cells in amphibian regeneration. Nat. Rev. Mol. Cell Biol. 2002, 3:566-574.
3. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
4. Caplan A.I., Dennis J.E. Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 2006, 98:1076-1084.
5. Jones B.J., McTaggart S.J. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp. Hematol. 2008, 36:733-741.
6. Iyer S.S., Rojas M. Anti-inflammatory effects of mesenchymal stem cells novel concept for future therapies. Expert Opin. Biol. Ther. 2008, 8:569-581.
7. Holmes B. The regeneration game: getting all touchy-feely. New Sci. 2010, 205(2747):36-39.
8. Caplan A.I. Mesenchymal stem cells. J. Orthop. Res. 1991, 9:641-650.
9. Caplan A.I. The mesengenic process. Clin. Plast. Surg. 1994, 21:429-435.
10. Horwitz E.M., Le Blanc K., Dominici M., Mueller I., Slaper-Cortenbach I., Marini F.C., Deans R.J., Krause D.S., Keating A. Clarification of the nomenclature for MSC: the international society for cellular therapy position statement. Cytotherapy 2005, 7:393-395.
11. Lin P., Correa D., Kean T.J., Awadallah A., Dennis J.E., Caplan A.I. Serial transplantation and long-term engraftment of intra-arterially delivered clonally derived mesenchymal stem cells to injured bone marrow. Mol. Ther. 2014, 22:160-168.
12. Crisan M., Yap S., Castella L., Chen C.W., Corselli M., Park T.S., Andriolo G., Sun B., Zheng B., Zhang L., Norotte C., Teng P.-N., Traas J., Schugar R., Deasy B.M., Badylak S., Buhring H.-J., Giacobino J.-P., Lazzari L., Huard J., Peault B. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008, 3:301-313.
13. Caplan All A.I. MSCs are pericytes?. Cell Stem Cell 2008, 3:229-230.
14. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoitic tissues. Science 1997, 276:71-74.
15. Caplan A.I., Correa D. The MSC: an injury drugstore. Cell Stem Cell 2011, 9:11-15.
16. Caplan A.I. What's in a name?. Tissue Eng. Part A 2010, 16(8):2415-2417.
17. Bensidhoum M., Gobin S., Chapel A., Lemaitre G., Bouet S., Waksman G., Thierry D., Martin M.T. Therapeutic effect of human mesenchymal stem cells in skin after radiation damage. J. Soc. Biol. 2005, 199(4):337-341.
18. Bergers G., Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro-oncol. 2005, 7(4):452-464.
19. Sorrell J.M., Baber M.A., Caplan A.I. Influence of adult mesenchymal stem cells on in vitro vascular formation. Tissue Eng. Part A 2009, 15:17511-21761.
20. Lazarus H.M., Haynesworth S.E., Gerson S.L., Rosenthal N.S., Caplan A.I. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant. 1995, 16:557-564.
21. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
22. Bonfield T.L., Caplan A.I. Adult mesenchymal stem cells: an innovative therapeutic for lung diseases. Discov. Med. 2010, 9(47):337-345.
23. Itescu S., Schuster M.D., Kocher A.A. New directions in strategies using cell therapy for heart disease. J. Mol. Med. 2003, 81:288-296.
24. Giordano A., Galderis U., Marino I.R. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J. Cell. Physiol. 2007, 211:27-35.
25. Ankrum J.A., Ong J.F., Karp J.M. Mesenchymal stem cells: immune evasive, not immune privileged. Nat. Biotechnol. 2014, 32(3):252-260.
26. Holt V., Caplan A.I., Haynesworth S.E. Identification of a subpopulation of marrow MSC-derived medullary adipocytes that express osteoclast-regulating molecules. PLOS ONE 2014, 9(10):e108920.
27. Haynesworth S.E., Goldberg V.M., Caplan A.I. Diminution of the number of mesenchymal stem cells as a cause for skeletal aging. Musculoskeletal Soft-Tissue Aging: Impact on Mobility, Section 1 1994, 79-87. American Academy of Orthopaedic Surgeons Publishers, (Chapter 7). J.A. Buckwalter, V.M. Goldberg, S.L.-Y. Woo (Eds.).
28. Allen J.E., Wynn T.A. Evolution of Th2 immunity: a rapid repair response to tissue destructive pathogens. PLoS Pathog 2011, 7(5):e1002003.
29. Jackson W.M., Nesti L.J., Tuan R.S. Mesenchymal stem cell therapy for attenuation of scar formation during wound healing. Stem Cell Res. Ther. 2012, 3(3):20.
30. Williams A.R., Suncion V.Y., McCall F., Guerra D., Mather J., Zambrano J.P., Heldman A.W., Hare J.M. Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling. Heart Assoc. 2013, 2:e000140.
31. Haynesworth S.E., Baber M.A., Caplan A.I. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 1992, 13:69-80.
32. Barry F., Boynton R., Murphy M., Zaia J. The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2001, 289:519-524.
33. Chamerlain G., Fox J., Ashton B., Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential homing. Stem Cells 2007, 25:2739-2749.
34. Colgan S.P., Eltzschig H.K., Eckle T., Thompson L.F. Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal. 2006, 2:351-360.
35. Adair T.H. Growth regulation of the vascular system: an emerging role for adenosine. Am. J. Physiol. 2005, 289:R283-R296.
36. 2A receptors play an active role in mouse bone marrow-derived mesenchymal stem cell development. J. Leukoc. Biol. 2009, 85:438-444.
37. Antonioli L., Pacher P., Vizi E.S., Haskó G. CD39 and CD73 in immunity and inflammation. Trends Mol. Med. 2013, 19:355-367.
38. Carroll S.H., Ravid K. Differentiation of mesenchymal stem cells to osteoblasts and chondrocytes: a focus on adenosine receptors. Expert Rev. Mol. Med. 2013, 15:e1.
39. 2B receptors in bone marrow cells from normal humans and patients with multiple myeloma. FASEB J. 2013, 27:1-9.
40. Mediero A., Cronstein B.N. Adenosine and bone metabolism. Trends Endocrinol. Metab. 2013, 24:290-300.
41. Iger I.C., Bracco P.A., Gonçalves C.E.I., Zanin R.F., Nardi N.B., Lenz G., Battastini A.M.O., Wink M.R. Mesenchymal stem cells from different murine tissues have differential capacity to metabolize extracellular nucleotides. J. Cell. Biochem. 2014, 115:1673-1682.
42. Kaebish C., Schipper D., Babczyk P., Tobiasch E. The role of purinergic receptors in stem cell differentiation. Comput. Struct. Biotechnol. J. 2015, 13:75-84.
43. Sattler C., Steinsdoerfer M., Offers M., Fisher E., Schierl R., Heseler K., Däubener K., Seissler J. Inhibition of T-cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation. Cell Transplant. 2011, 20:1221-1230.
44. Ciciarello M., Zini R., Rossi L., Salvestrini V., Ferrari D. Extracellular purines promote the differentiation of human bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 2013, 22:1097-1111.
45. Lee J.J., Jeong H.J., Kim M.K., Wee W.R., Lee W.W., Kim S.U., Sung C., Yang Y.H. CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human TH17 cell function. Purinergic Signal. 2014, 10:357-365.
46. Saldanha-Araujo F., Ferreira F., Palma P.V., Araujo A.G., Queiroz R.H.C., Covas D.T., Zago M.A., Panepucci R.A. Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes. Stem Cell Res. 2011, 7:66-74.
47. Amarnath S., Foley J.E., Farthing D.E., Gress R.E., Laurence A., Eckhaus M.A., Metais J.-Y., Rose J.J., Hakim F.T., Felizardo T.C., Cheng A.V., Robey P.G., Stroncek D.E., Sabatino M., Battwwalla M., Ito S., Fowler O.H., Barrett A.J. Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivo. Stem Cells 2015, 33:1200-1212.
48. Ringden O., Uzunel M., Rasmusson I., Remberger M., Sundberg B., Lonnies H., Marschall H.U., Dlugosz A., Szakos A., Hassan Z., Omazic B., Aschan J., Barkholt L., Le Blanc K. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
49. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., Lanino E., Sundberg B., Bernardo M.E., Remberer M., Dini G., Egeler R.M., Bacigalupo A., Fibbe W., Ringden O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
50. Brockes J.P. Amphibian limb regeneration: rebuilding a complex structure. Science 1997, 276(5309):1-87.
51. Turner N.J., Johnson S.A., Badylak S.F. A histomorphologic study of the normal healing response following digit amputation in C57bl/6 and MRL/MpJ mice. Arch. Histol. Cytol. 2010, 73(2):3-111.
52. Fernando W.A., Leininger E., Simkin J., Li N., Malcom C.A., Sathyamoorthi S., Han M., Muneoka K. Wound healing and blastema formation in regenerating digit tips of adult mice. Dev. Biol. 2011, 301-310.
53. Agrawal V., Tottey S., Johnson S.A., Freund J.M., Siu B.F., Badylak S.F. Recruitment of progenitor cells by an extracellular matrix cryptic peptide in a mouse model of digit amputation. Tissue Eng. Part A 2011, 17(19-20):2435-2443.
54. Kenyon J., Sadeghi Z., Tomechko S., Leahy P., Daneshgari F., Caplan A.I., Hijaz A. Cytokine expression analysis of human MSC and injured rat tissue in a model of stress urinary incontinence. 12th Annual ISSCR Meeting 2014, (Abstract).
55. Caplan A.I. Cartilage begets bone versus endochondral myelopoiesis. Clin. Orthop. Relat. Res. 1990, 261:257-267.
56. Bernardo M.E., Fibbe W.E. Mesenchymal stromal cells: sensor and switchers of inflammation. Cell Stem Cell 2013, 13:392-402.
57. Sims D.E. Diversity within pericytes. Clin. Exp. Pharmacol. Physiol. 2000, 27(10):842-846.
58. Singer M. Neurotrophic control of limb regeneration in the newt. Ann. N. Y. Acad. Sci. 1974, 228:308-321.
59. Hay E.D., Fischman D.A. Origin of the blastema in regenerating limbs of the newt Triturus viridescens: an autoradiographic study using tritiated thymidine to follow cell proliferation and migration. Dev. Biol. 1961, 3(1):26-59.
60. Krasnodembskaya A., Song Y., Fang X., Gupta N., Serikov V., Lee J.W., Matthay M.A. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL037. Stem Cells 2010, 28:2229-2238.
61. Bonfield T.L., Koloze M., Lennon D.P., Zuchowski B., Yang S.E., Caplan A.I. Human mesenchymal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model. Am. J. Physiol. 2010, 299:L760-L770.
62. Wright K.T., Masri W.E., Osman A., Chowdhury J., Johnson W.E.B. Concise review: bone marrow for the treatment of spinal cord injury: mechanisms and clinical applications. Stem Cells 2011, 29(2):69-78.